ENTA - Enanta Pharmaceuticals Inc logo

Enanta Pharmaceuticals Inc

ENTA

Enanta Pharmaceuticals develops small molecule drugs targeting viral infections and liver diseases. Its pipeline includes treatments for hepatitis B, respiratory syncytial virus, and hepatitis C, with collaborations for protease inhibitors.

โš•๏ธ Healthcare NASDAQ Listed 2013 $ USD
$1,000 invested 10 years ago โ†’$483today

Score Overview

1 Year
Score
Net Growth22.79%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-0.10%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score3.7
Net Growth19.96%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-32.77%
Rev TrendNever
Revenue Consistencyโ€”
10 Years
Score
Net Growth-391.84%
Net Trend40%
Net Income Consistency
Rev Growth-26.07%
Rev Trend20%
Revenue Consistency
All Time
Score
Net Growth-6x
Net Trend46%
Net Income Consistency
Rev Growth103.59%
Rev Trend31%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Enanta Pharmaceuticals Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 30 years of fundamentals. ENTA does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-01
$ 12.84โ€”
1 Year2025-10-01
$ 10.6121.02%
5 Years2021-10-01
$ 60.96-78.94%
10 Years2016-09-30
$ 26.61-51.75%
All Time2013-03-21
$ 17.18-25.26%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 65M-$ 63M$ 189M
2025$ 65M-$ 81M$ 188M
2024$ 67M-$ 116M$ 248M
2023$ 79M-$ 133M$ 369M
2022$ 86M-$ 121M$ 249M
2021$ 97M-$ 78M$ 244M
2020$ 122M-$ 36M$ 386M
2019$ 205M$ 46M$ 335M
2018$ 206M$ 71M$ 308M
2017$ 102M$ 17M$ 223M
2016$ 88M$ 21M$ 210M
2015$ 160M$ 78M$ 145M
2014$ 47M$ 34M$ 90M
IPO2013$ 32M$ 9M$ 101M
ENTA - Enanta Pharmaceuticals Inc logo

Enanta Pharmaceuticals Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 122M to $ 65M and net income went from -$ 36M to -$ 81M. Revenue increased in 0 of those 5 years; net income in 3.

Between 2015 and 2025, revenue declined from $ 160M to $ 65M and net income went from $ 78M to -$ 81M. Revenue increased in 2 of those 10 years; net income in 4.

Enanta Pharmaceuticals Inc currently holds a 5-year HDB Score of 3.7 out of 10. How the HDB Score is calculated.

Membership

Explore ENTA with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,813 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies